NANCY HART: Open Payments
NPI 1073536603 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,806 in 98 payments from 17 companies in 2025. Trend: 2023 $1,058 · 2024 $1,422 · 2025 $1,806
Food & beverage: $1,806
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $297 |
| Teva Pharmaceuticals USA, Inc. | 26 | $292 |
| Otsuka America Pharmaceutical, Inc. | 14 | $211 |
| E.R. Squibb & Sons, L.L.C. | 9 | $161 |
| Vanda Pharmaceuticals Inc. | 5 | $147 |
| Lundbeck LLC | 6 | $128 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $114 |
| Corium, LLC | 4 | $92 |
| Alkermes, Inc. | 4 | $91 |
| Janssen Pharmaceuticals, Inc | 3 | $73 |
Products named: INGREZZA, REXULTI, AUSTEDO XR, COBENFY, FANAPT, CAPLYTA, Azstarys, ARISTADA.
Industry payments across FL — which companies pay providers there.
